© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > TNO155
<< Back to September
first-in-class allosteric SHP2 phosphatase inh.
oral agent in multiple trials for cancer
from 1.5M cmpd biochemical HTS + SBDD
J. Med. Chem., Sep. 24, 2020
Novartis, Cambridge, MA
TNO155 is an allosteric inhibitor of the SHP2 phosphatase, which has been a hot target in oncology recently due to its promotion of mutant KRAS activity as well as its…
Unlock this content with a Premium membership to read it now.